Search for: "Eli Lilly "
Results 1341 - 1360
of 2,131
Sort by Relevance
|
Sort by Date
9 Nov 2010, 4:30 am
The state's case was based on claims that J&J and Janssen sent 7,604 "Dear Doctor" letters to Louisiana medical providers and made a total of 27,542 sales calls, in which company representatives claimed that Risperdal was safer than competing antipsychotic drugs such as Eli Lilly's Zyprexa and AstraZeneca's Seroquel. [read post]
8 Nov 2010, 12:39 pm
The firm is advising drug giant Eli Lilly on its purchase of privately held Avid Radiopharmaceuticals in a deal worth up to $800 million. [read post]
8 Nov 2010, 5:22 am
Eli Lilly said Monday that it had agreed to buy Avid Radiopharmaceuticals' outstanding stock for an upfront payment of $300 million, and up to $500 million to follow. [read post]
4 Nov 2010, 9:13 pm
Eli Lilly & Co., No. 2010-1105 (Fed. [read post]
3 Nov 2010, 12:46 pm
., Pfizer ($2.3 billion settlement for marketing of Bextra), Eli Lilly ($1.4 billion settlement for marketing of Zyprexa), and TAP Pharmaceutical ($875 million for marketing of Lupron). [read post]
3 Nov 2010, 1:21 am
Highlights this week included: US Supreme Court to hear Bayh-Dole patent ownership dispute: Stanford v Roche (Patently-O) (IPKat) (IPBiz) US DoJ amicus brief in Myriad says no to patentability of genomic DNA: AMP v USPTO (IPBiz) (Inventive Step) (Patently-O) (Patent Docs) (Holman’s Biotech IP Blog) Gemzar (Gemcitabine) – US: CAFC denies en banc rehearing of ‘distorted’ law of double-patenting: Sun Pharmaceuticals v Eli Lilly (Peter Zura’s 271 Patent… [read post]
1 Nov 2010, 2:10 pm
Eli Lilly and Company (Fed. [read post]
1 Nov 2010, 7:00 am
Recent case law in Italy had concluded, however, that the simple filing of a market authorization does not constitute evidence of an infringing activity (Court of Milan June 11, 2009, Eli Lilly v. [read post]
31 Oct 2010, 9:06 pm
Eli Lilly and Company 3:10-cv-05584; filed October 27, 2010 in the District Court of New Jersey Declaratory judgment that Zydus may proceed with the manufacture and sale, in conjunction with Zydus' approved ANDA, of a generic version of Eli Lilly's Strattera® (atomoxetine hydrochloride, used to treat attention-deficit/hyperactivity disorder), based on a finding of invalidty of U.S. [read post]
29 Oct 2010, 8:58 am
William Leak was able to secure a job with drugmaker Eli Lilly as a promotional speaker and adviser. [read post]
27 Oct 2010, 8:30 am
Written by Michael Davitz M.D. [read post]
27 Oct 2010, 3:38 am
General GSK forms alliance for development of gene therapy techniques for rare diseases (Patent Docs) Emerging economies’ new initiative on falsified and substandard medicines (IP Watch) Michèle Rivasi asks question about ACTA and Access to Medicine (KEI) As negotiators launch talks on biodiversity, industry requests IP protection (IP Watch) Negotiators persist on biodiversity benefit-sharing treaty despite slipping deadlines (IP Watch) New draft biodiversity treaty text shows much work… [read post]
25 Oct 2010, 4:30 am
Eli Lilly & Co., No. 09-5004-CV, 2010 WL 3853003 (2d Cir. [read post]
19 Oct 2010, 2:54 pm
A new osteoporosis drug developed by Eli Lilly and Company has proven effective in regnerating jaw bone in patients who suffer from "dead jaw" or osteonecrosis of the jaw. [read post]
19 Oct 2010, 12:20 pm
Eli Lilly & Co., 2010 WL 4024922 (D.S.D. [read post]
19 Oct 2010, 9:09 am
One company, Eli Lilly, was responsible for a large amount of the Harvard payments, including 50 percent in 2009 and 33 percent in the first three months of 2010. [read post]
12 Oct 2010, 8:56 pm
Apotex asks Supreme Court to review generic Cozaar/Hyzaar 180-day exclusivity decision (FDA Law Blog) Faslodex (Fulvestrant) – US: AstraZeneca seeks review of BPAI decision concerning patent covering ‘Use of Fulvestrant in treatment of resistant breast cancer’ (Patent Docs) Gemzar (Gemcitabine) – US: Eli Lilly files patent infringement complaint against Dr Reddy’s following Para IV certification (Patent Docs) Lipitor (Atorvastatin) – US: Generic… [read post]
11 Oct 2010, 5:56 am
Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. [read post]
10 Oct 2010, 6:21 am
Also brought within the IPO’s corral is the decision in Dr Reddy’s Laboratories (UK) Ltd v Eli Lilly & Co Ltd [2010] RPC 8 (noted by the IPKat here), in which the Court of Appeal delved into the murky depths of selection invention – asking, in the process, where a wise man would hide a leaf… The sections on supplementary protection certificates has also been updated in light of the decisions of the High Court in Yeda Research and Development Company Ltd… [read post]
6 Oct 2010, 7:46 am
Eli Lilly and Co., 2010 WL 3892464, at *1 (S.D. [read post]
